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THE LANCET • Vol 362 • July 5, 2003 • www.thelancet.com 77 CORRESPONDENCE admitted in varying degrees of severity to the medical ward, but all were eventually sent to the ICU. Seven of the 11 patients needed to be intubated.
The 241 non-infected hospital staff worked in the following departments: 86 (36%) ICU, 81 (34%) general medicine, 49 (20%) infection isolation unit, 19 (8%) accident and emergency, and six (2%) in other departments. Most staff were, therefore, from the ICUs and the infection isolation units, and none was infected. In the early days of the SARS outbreak, these departments would probably have been more vigilant with respect to SARS infection and have had better control measures in place than other departments.
Furthermore, the diagnoses of these index cases were already known when they were admitted to these units, which might not have been the case in individuals admitted to general medical wards, where most of the 13 infected staff worked.
Diagnosis of SARS in the 11 cases was confirmed by a four-fold rise of antibodies to corona-like viruses associated with SARS. The severity of their illness indicates that the initial viral replication phase, as reported by Peiris and colleagues, 1 must have passed, making the patient highly infectious. Furthermore, the various departments where SARS cases are usually managed, including the ICU, are well represented in our study. Thus, the validity of our conclusions ought not to be diminished by the questions raised by Tong.
Tong also mentions that coughing produces particles of less than 1 m in size and that surgical masks might not, therefore, provide adequate protection against disease. However, that these small particles, which are generated even in normal breathing, 2 play an important part in the spread of all respiratory infections has not been verified. Coughing is therefore not a criterion for ascertaining whether a disease is airborne. Rather, the actual pattern of spread is used for establishing the mode of transmission of an infection. On this basis, precautions against droplets, including use of a surgical mask, are recommended in the Centers for Disease Control (USA) Guidelines 3 for the isolation of most respiratory infections, including diphtheria, mycoplasma, pneumonic plague, adenovirus, influenza, mumps, parvovirus B19, and rubella. Our conclusion that droplets are the mode of transmission of SARS simply suggests that the disease is similar to most other respiratory infections. terminal, receptor-binding domain, S1. Kontoyiannis and co-workers also suggested that the putative SARS coronavirus receptor activity of aminopeptidase N could be blocked with a small molecule that inhibits its enzymatic activity, ubenimex, and suggested that this molecule be explored to prevent infection of health-care workers with SARS coronavirus and to treat travellers returning from southeast Asia who develop pneumonia. Results of our studies 2 indicate that high concentrations of ubenimex or actinonin, both small competitive inhibitors of the enzymatic activity of aminopeptidase N, are unable to inhibit infection with human coronavirus strain 229E. Moreover, the enzymatic activity of aminopeptidase N is not needed for its use as a receptor for group 1 coronaviruses. 5 Since aminopeptidase N has not been established as a cellular receptor for SARS coronavirus, and since competitive inhibitors of aminopeptidase N do not inhibit human coronavirus 229E recognition of its aminopeptidase N receptor, it is not reasonable to use ubenimex to prevent or treat SARS.
*W H Seto, D Tsang
Identification of a receptor for SARS coronavirus would be an important first step toward discovery of receptor-based antivirals for prophylaxis or therapeutics. Such antivirals, however, should be firmly established through invitro and preclinical testing before being considered for use against SARS. In their Correspondence letter, Dimitrios Kontoyiannis and colleagues (May 3, p 1558) 1 suggest that the receptor for the SARS coronavirus is CD13 or human aminopeptidase N, apparently based on our work 2 showing that aminopeptidase N is the receptor for human respiratory coronavirus 229E, which causes upper respiratory tract infection. We showed that some monoclonal antibodies directed against aminopeptidase N blocked virus binding and entry into susceptible cells. We also showed that a blocking monoclonal antibody directed against murine CEACAM1a, the receptor for murine coronavirus (mouse hepatitis virus; MHV), inhibits murine coronavirus infection in vitro and in vivo. 3, 4 Thus, monoclonal antibodies or Fab fragments directed against a receptor for SARS coronavirus could be useful in prevention or treatment of SARS in close contacts of infected individuals.
However, there is no experimental evidence to suggest that aminopeptidase N is a receptor for SARS coronavirus. Importantly, the aminoacid sequences of the spike glycoproteins of SARS coronavirus, human respiratory coronavirus 229E, and murine coronavirus differ greatly, especially in the N-
